<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786173</url>
  </required_header>
  <id_info>
    <org_study_id>PRIME</org_study_id>
    <nct_id>NCT02786173</nct_id>
  </id_info>
  <brief_title>Peripheral Registry of Endovascular Clinical Outcomes &quot;The PRIME Registry&quot;</brief_title>
  <acronym>PRIME</acronym>
  <official_title>Peripheral Registry of Endovascular Clinical Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metro Health, Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Terumo Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiovascular Systems Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spectranetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Metro Health, Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PRIME Registry is a multi-center, observational study designed to evaluate immediate and
      long-term outcomes (36 months) of endovascular revascularization in patients with critical
      limb ischemia (CLI) and advanced peripheral artery disease (PAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Peripheral RegIstry of Endovascular Clinical OutcoMEs (PRIME Registry) represents the
      collaborative effort among three centers across the US with the goal of reaching 10 sites
      globally. PRIME explores all aspects of advanced peripheral arterial disease (PAD) and
      critical limb ischemia (CLI) care including the collection of comprehensive clinical,
      diagnostic, procedural, and follow-up data for three years following an index endovascular
      procedure. Data collection activities began in January of 2013 with the goal of collecting
      data on 5,000 subjects. Analysis of this multi-site registry will produce generalizable
      findings that describe the clinical epidemiology and management practices of advanced PAD and
      CLI patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Amputation free survival rates</measure>
    <time_frame>At 36 month follow-up visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Access site and procedural complications</measure>
    <time_frame>At 36 month follow-up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>At 36 month follow-up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>At 36 month follow-up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>At 36 month follow-up visit</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Peripheral Vascular Disease</condition>
  <condition>Critical Limb Ischemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are to receive or have received lower extremity endovascular treatment for
        peripheral artery disease.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are to receive or have received lower extremity endovascular intervention

          -  Rutherford III-VI Classification

          -  Ability to provide informed consent within 30 day prior to 60 days post index
             endovascular intervention.

          -  Ability to follow up at enrollment site.

        Exclusion Criteria:

          -  Inability or unwillingness to consent for participation in the registry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihad A Mustapha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theresa McGoff, BSN, RN</last_name>
    <phone>616-252-8116</phone>
    <email>theresa.mcgoff@metrogr.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Dupont</last_name>
      <phone>321-841-1505</phone>
      <email>ashley.dupont@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Farhan Khawaja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prairie Heart</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelse Mather</last_name>
      <phone>217-492-9100</phone>
      <phone_ext>122</phone_ext>
      <email>kmather@prairieresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ashraf Al-Dadah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Metro Health Hospital</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa McGoff, BSN, RN</last_name>
      <phone>616-252-8116</phone>
      <email>theresa.mcgoff@metrogr.org</email>
    </contact>
    <investigator>
      <last_name>Larry Diaz-Sandoval, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barbara Karenko, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cox Health</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Weatherfield</last_name>
      <phone>417-269-0599</phone>
      <email>Amy.Weatherfield@coxhealth.com</email>
    </contact>
    <investigator>
      <last_name>John (Randy) Mullins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rex Healthcare</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivy Smith</last_name>
      <phone>770-668-4972</phone>
      <email>ivy.smith@unchealth.unc.edu</email>
    </contact>
    <investigator>
      <last_name>George Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2016</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PRIME</keyword>
  <keyword>PAD</keyword>
  <keyword>PVD</keyword>
  <keyword>Observational</keyword>
  <keyword>CLI</keyword>
  <keyword>PRIME Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

